ABSTRACT
Despite these apparent advantages, the exact use of IV immunoglobulin therapy in the prevention of CMV disease in solid organ transplantation remains to be determined. The optimal dose, duration of therapy, and mechanism of action all need further clarification. Current prophylactic approaches using immunoglobulins, either with or without antiviral agents, vary significantly among transplant programs. This variation reflects the relative lack of large multicenter randomized trials and the fact that small, single-center studies are frequently difficult to interpret. Moreover, inherent differences in the type of solid organ transplanted should be considered, since prophylaxis found to be effective for one type of solid organ transplant may not necessarily apply to another. Until more data are collected, the use of immunoglobulins in solid organ transplantation will continue to vary depending on the potential risk of infection in the recipient, the type of solid organ transplanted, and the specific regimen utilized by the transplant center.
